Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Cellbxhealth Plc ADR
(OP:
ANPCY
)
0.0670
UNCHANGED
Last Price
Updated: 2:45 PM EST, Dec 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cellbxhealth Plc ADR
< Previous
1
2
3
4
5
6
Next >
Angle PLC Announces Streamlining of Operations to Increase Cash Runway
October 18, 2022
Via
ACCESSWIRE
Angle PLC announces TR-1: Notification of major holdings
October 17, 2022
Via
ACCESSWIRE
Angle PLC Announces First Regional Distribution Agreement
October 12, 2022
Via
ACCESSWIRE
Angle PLC Announces Holding(s) in Company
September 30, 2022
Via
ACCESSWIRE
Angle PLC Announces Issue of Equity
September 30, 2022
Via
ACCESSWIRE
Angle PLC Announces Interim Results
September 29, 2022
Via
ACCESSWIRE
Angle PLC Announces Positive Headline Results From Ovarian Study
September 29, 2022
Via
ACCESSWIRE
Angle PLC announces Study using Parsortix in head and neck cancer
September 28, 2022
Via
ACCESSWIRE
Angle PLC Announces New Poster Presented at ASCP Meeting
September 13, 2022
Via
ACCESSWIRE
Angle PLC Announces Novel Assay; Predicts Malignancy in Pelvic Mass
September 12, 2022
Via
ACCESSWIRE
Angle PLC Announces Notice of Interim Results and Webcast
September 01, 2022
Via
ACCESSWIRE
Angle PLC Announces Issue of Equity
July 08, 2022
Exercise of Options and Total Voting Rights
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Result of 2022 Annual General Meeting
June 29, 2022
GUILDFORD, SURREY / ACCESSWIRE / June 29, 2022 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today,...
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Spread of Breast Cancer Accelerates During Sleep
June 27, 2022
BREAKTHROUGH RESEARCH WITH PARSORTIX REVEALS SPREAD OF BREAST CANCER ACCELERATES DURING SLEEP
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Issue of Equity
June 23, 2022
Exercise of Options and Total Voting Rights
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Secured Contract From Pharma Services Customer
June 22, 2022
Additional contract for a new clinical trial
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Predicting Immunotherapy Response in SCLC
June 16, 2022
PARSORTIX SYSTEM DEMONSTRATES POTENTIAL IN PREDICTING IMMUNOTHERAPY RESPONSE IN SMALL CELL LUNG CANCER
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Potential Role of Invasive Cellular Protrusions
June 14, 2022
Prostate cancer cells may use invasive cellular protrusions to aid entry into the blood stream, a potential target in the metastatic process for novel therapy development
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Partnership with Major United States Urology Group
May 30, 2022
PARTNERSHIP ESTABLISHED WITH A MAJOR UNITED STATES UROLOGY GROUP TO CONDUCT CLINICAL STUDIES IN PROSTATE CANCER AND AS A POTENTIAL ROUTE TO MARKET
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Molecular Characterisation of CTCs
May 27, 2022
Parsortix system harvests intact CTCs for single-cell whole genomic sequencing from frozen and fresh blood samples with the same efficiency
From
ANGLE plc
Via
AccessWire
ANGLE receives FDA clearance for Parsortix
May 25, 2022
ANGLE ACHIEVES WORLD FIRST WITH FDA CLEARANCE FOR ITS PARSORTIX SYSTEMFDA De Novo product clearance to harvest cancer cells from blood for subsequent analysis offers the prospect of a new era of...
From
ANGLE plc
Via
AccessWire
Angle PLC - Prostate Cancer UK Funds New Study Using Parsortix
May 20, 2022
Research Into the Use of Parsortix-Based CTC Blood Test To Assess Whether Prostate Cancer Patients Require Prostatectomy SurgeryPotential for a New Standard of Care in an Area of High Unmet Medical...
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Preliminary Results
April 28, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Notice of Preliminary Results and Webcast
April 20, 2022
GUILDFORD, UK / ACCESSWIRE / April 20, 2022 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, will be releasing its preliminary results for the year ended 31 December 2021 on...
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Poster on Parsortix System Presented at AACR 2022
April 14, 2022
PARSORTIX SYSTEM RESULTS PUBLISHED AS A POSTER AT LEADING CANCER CONFERENCE AACR 2022 Poster demonstrated use of Parsortix workflow for triple negative breast cancer GUILDFORD, UK / ACCESSWIRE / April...
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Identifying Drug Targets in Cancer Metastasis
April 01, 2022
PARSORTIX SYSTEM DEMONSTRATES ABILITY TO ISOLATE CTCs FOR DOWNSTREAM MOLECULAR ANALYSIS, IDENTIFYING KEY DRUG TARGETS INVOLVED IN CANCER METASTASIS - World-class research identifies specific genetic...
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Rapid Information on Patient Response to Therapies
March 29, 2022
PARSORTIX SYSTEM SHOWS POTENTIAL FOR PROVIDING RAPID INFORMATION ON PATIENT RESPONSE TO THERAPIES TARGETING METASTASIS - Existing chemotherapies, such as vinorelbine, may selectively target and reduce...
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Identifying Therapeutic Targets in TNBC Patients
March 25, 2022
PARSORTIX SHOWS POTENTIAL FOR IDENTIFYING THERAPEUTIC TARGETS IN PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER - Parsortix system harvests intact CTCs for whole genome sequencing identifying multiple...
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Update on Laboratory Accreditation
March 15, 2022
ANGLE's US clinical laboratory issued Certificate of Registration, a key step to achieving CLIA accreditation GUILDFORD, UK / ACCESSWIRE / March 15, 2022 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a...
From
ANGLE plc
Via
AccessWire
Angle PLC Announces Holding(s) in Company
March 02, 2022
GUILDFORD, SURREY / ACCESSWIRE / March 2, 2022 / ANGLE plc (OTCQX:ANPCY )(AIM:AGL) TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB0034330679 Issuer Name ANGLE plc UK or...
From
ANGLE plc
Via
AccessWire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.